Lung transplant

AI Therapeutics Launches Phase 2 Trial of LAM-001 for Bronchiolitis Obliterans Syndrome Post-Lung Transplant

AI Therapeutics, a forward-looking clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for rare diseases, has announced the initiation of ...